ClinicalTrials.gg
Not yet recruitingNCT07939867Updated Nov 16, 2026

Pharmacokinetics of Engasertib in Participants With and Without Hepatic Impairment

A Phase 1 interventional study of Engasertib in Hepatic Impairment, sponsored by Vaderis Therapeutics AG. Not yet recruiting. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Vaderis Therapeutics AG · Phase 1, Interventional, and Basic science

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The main objective of this trial is to compare the pharmacokinetics (PK) of engasertib in plasma following administration of a single oral dose in adult participants with mild to moderate hepatic impairment relative to age- and body weight-matched participants without hepatic impairment.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Hepatic Impairment
  • Engasertib
  • VAD044
03

In context

Lead sponsor

Vaderis Therapeutics AG is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18 to 70 years (both inclusive), at the time of signing the .
  • Body weight ≥ 50 kg and a (BMI) within the range 18 to 35 kg/m\^2 (both inclusive) at screening.
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.
  • Non-smoker, former smoker or stable non-smoker for at least 3 months prior to screening. Participants must also have abstained from use of other nicotine containing products for at least 3 months before screening.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol prior to any clinical trial specific procedure.

Participants without hepatic impairment (Cohort 1) only:

  • Overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs and (ECG).
  • Clinically acceptable results of clinical chemistry, hematology, coagulation, and urinalysis at screening.
  • No known or suspected hepatic impairment; including at screening, meet all the following criteria, as assessed by central laboratory: a) (ALT) ≤ 1.1 x (ULN); b) aspartate aminotransferase (AST) ≤ 1.2 x ULN; c) Total serum ≤ 1.2 x ULN; d) Serum albumin ≥ lower limit of normal (LLN); e) ≤ 1.2 x ULN.
  • Participant meets the demographic-matching criteria, including body weight (kg) ± 20 % and age ± 15 years of the average of the pooled hepatic impairment cohorts (Cohorts 2 and 3). Attempts will be made to ensure that the male-to-female distribution in Cohort 1, is comparable (i.e., ± 1) to that in the pooled hepatic impairment cohorts (Cohorts 2 and 3).

Participants with impaired hepatic function (Cohorts 2 and 3 only):

  • Documented diagnosis of hepatic impairment that meets the criteria for Class A or B of the classification, with no change in disease status within the 28 days prior to the screening visit, as documented by the participant's recent medical history (e.g., no worsening clinical signs of hepatic impairment, no worsening of total bilirubin or prothrombin time by more than 50%).
  • Participant is willing and able to abide by the lifestyle guidelines described in the protocol.

Exclusion criteria

Exclusion Criteria:

  • medical condition or that may significantly alter the absorption, metabolism or elimination of engasertib, constitute a safety risk, or interfere with interpretation of trial results.
  • History or evidence of malabsorption, or gastrointestinal surgery or disease that may significantly affect the absorption, distribution, metabolism or excretion of engasertib.
  • Known or suspected to engasertib or any component of its formulation.
  • Clinically significant infection or immunodeficiency, including relevant active viral infection.
  • Use of prohibited concomitant medications or therapies that may interfere with the pharmacokinetics of engasertib within the protocol-defined period before dosing.
  • Use of another drug or participation in another clinical trial within 30 days or 5 half-lives of the prior trial intervention, whichever is longer.
  • Clinically significant abnormalities in vital signs, , or renal function that preclude participation.
  • Positive screening for alcohol or drugs of abuse, except where a positive drug screen in participants with hepatic impairment can be explained by permitted concomitant medication.
  • Positive pregnancy test in a female participant of .
  • For Cohorts 2 and 3: clinically relevant disease other than hepatic impairment and its associated manifestations that may affect safety, PK interpretation, or assessment.
  • For Cohorts 2 and 3: potentially infectious liver disease, including or C.
  • For Cohorts 2 and 3: hepatic carcinoma, hepatorenal syndrome, predicted of less than 1 year, severe portal hypertension, severe ascites requiring frequent paracentesis, severe hepatic encephalopathy, recent gastrointestinal hemorrhage, or previous kidney, liver, or heart transplantation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Cohort 1: No Hepatic Impairment

    Participants without hepatic impairment will take a single oral dose of engasertib 40 mg.

    Drug: Engasertib

  • Experimental
    Cohort 2: Mild Hepatic Impairment

    Participants with mild hepatic impairment will take a single oral dose of engasertib 40 mg.

    Drug: Engasertib

  • Experimental
    Cohort 3: Moderate Hepatic Impairment

    Participants with moderate hepatic impairment will take a single oral dose of engasertib 40 mg.

    Drug: Engasertib

Interventions

  • Engasertib will be taken orally as capsules.

    Also known as: VAD044

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve (AUC) from Zero to the Last Quantifiable Concentration (AUC0-tlast) of Engasertib

    Time frame: Up to Day 12

  2. AUC from Zero to Infinity (AUC0-inf) of Engasertib

    Time frame: Up to Day 12

  3. Maximum Plasma Concentration (Cmax) of Engasertib

    Time frame: Up to Day 12

Secondary outcomes

  1. Amount Excreted (Ae) in Urine from Time Zero to 72 h (Ae0-72)of Engasertib

    Time frame: Up to Day 4

  2. Fraction Excreted (Fe) in Urine from Time Zero to 72 h [Fe (%)] of Engasertib

    Time frame: Up to Day 4

  3. Renal Clearance (CLr) of Engasertib

    Time frame: Up to Day 4

  4. Percentage of Participants who Experienced Teatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    Time frame: Up to Day 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Apr 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939867
Lead sponsor
Vaderis Therapeutics AG
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Vaderis Therapeutics AG
Contact
info@vaderis.com
844-823-3747 ext. +1
Katarzyna Jarus-Dziedzic, MD, PhD
principal investigator · BioResearch Group Sp. z o.o.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Engasertib

Start the discussion